Individuals currently suffering from respiratory illnesses are more likely to be infected with influenza or COVID-19, the two ...

Presented by Alliance for Aging Research {beacon} Health Care Health Care PRESENTED BY The Big Story Vaccine advisers to ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Additional evidence supports current guideline recommendations to treat all who are hospitalized with influenza with an ...

In a study of newborn piglets, infection with influenza A was associated with disruptions in the piglets' nasal and gut ...

Tom McAndrew, a computational scientist and associate professor in Lehigh's College of Health, recently published a paper in ...

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.